AstraZeneca Educational Webinar Series

Presented by AADE in association with AstraZeneca-US Medical Affairs, CVMD Division

This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 60 days after the live broadcast, so don't miss out!

This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.






Webinar Schedule for 2019:

All webinars will be held from 1:00-2:00 pm EST

February 13: 2019 Updates on Guidelines in the Management of T2D: Navigating CVOTs and Implications for Treatment

April 10: Cardio-Renal Complications of T2DM: Focus on Heart Failure 

June 26: Diabetic Kidney Disease: New Promise for Patients Fighting a Stubborn Nemesis? (Register now: www.diabeteseducator.org/event/webi190626)

August 28: Cardiovascular Outcomes Trials (CVOT) Update

October 23: SGLT-2 Inhibitors in Type 1 Diabetes

December 4: Lipids, HDL, High Triglycerides, and Cardiovascular Risk





Cardio-Renal Complications of Type 2 Diabetes: Focus on Heart Failure


Presented by John Venditto, MD, and Curtis Triplitt, PharmD, CDE will provide an overview of heart failure with a focus on diabetic cardiomyopathy as well as heart failure as a complication of type 2 diabetes. We will also review renal dysfunction as a complication of type 2 diabetes.

Upon completion of this activity, participants will be able to:

  1. Understand basic CV physiology of heart failure HpEF/HrEF
  2. Understand basic pathophysiology of heart failure in T2D
  3. Earlier identification of patients with T2D at risk for heart failure
  4. Understand basic pathophysiology of cardio-renal complications of T2D




Diabetic Kidney Disease: New Promise for Patients Fighting a Stubborn Nemesis?

Presented by Robert M. Perkins, MD, MPH, and Curtis Triplitt, PharmD, CDE, the live webinar will be on Wednesday, June 26, 2019 at 1:00 pm EST.
Register now: www.diabeteseducator.org/event/webi190626

After a nearly-two decade period of inactivity and failed trials in diabetic kidney disease (DKD), recent clinical trials have suggested that a new approach to this complication of diabetes may reduce kidney risk. This presentation will review important epidemiologic aspects of DKD, its natural history and pathophysiology, and current treatment approaches. Finally, we will discuss recent clinical trial advances and preview ongoing large, Phase 3 trial programs.

Upon completion of this activity, participants will be able to:

  1. Identify the major factors which drive kidney disease progression in Type 2 Diabetes
  2. Identify one new class of agents with potential to improve upon the current standard of care for diabetic kidney disease